Individuals with history of Capillary Leak Syndrome advised not to take Vaxzevria coronavirus (Covid-19) vaccine

Individuals with history of Capillary Leak Syndrome advised not to take Vaxzevria coronavirus (Covid-19) vaccine

The European Medicines Agency’s (EMA’s) safety committee (PRAC) has concluded that individuals who have a history of Capillary Leak Syndrome, should not be vaccinated with the Vaxzevria coronavirus (COVID-19) vaccine, formerly known as the AstraZeneca coronavirus vaccine. The Committee has further concluded that Capillary Leak Syndrome must be added to the vaccines product information as a side effect of the vaccine, together with ‘a warning to raise awareness among healthcare professionals and patients of this risk’. The EMA has advised that all individuals who have been vaccinated with Vaxzevria to seek immediate medical assistance, should they experience ‘rapid swelling of the arms and legs or sudden weight gain in the days following vaccination’. The EMA has further said that the above symptoms are often associated with feeling faint, due to low blood pressure.

EMA’s PRAC has said that it will continue to monitor for cases of the condition and will take any further actions necessary and has asked AstraZeneca to provide information regarding possible mechanisms for the development of Capillary Leak Syndrome following vaccination.

Source: Vaxzevria: EMA advises against use in people with history of capillary leak syndrome

Related Articles:
Latest Articles: